Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled versus intravenous levosimendan in children with pulmonary hypertension undergoing on-pump cardiac surgery
PACTR201911571076749Phase 0Completed
- Sponsor
- Mansoura University Children Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised, open-label trial of levosimendan in pulmonary arterial hypertension (PAH) and Cardiovascular Malformation (CVM) (3 arms), sponsored by Mansoura University Children Hospital. Primary endpoint: Assessment of intraoperative and postoperative systolic pulmonary artery pressure. Started Dec 2019; status: completed.
02
Drugs
levosimendan
03
Conditions
pulmonary arterial hypertension (PAH)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on PACTR201911571076749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201911571076749.